Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study

June 2022 in “ Journal of Clinical Medicine ”

Antonio Alcaraz, David Castro‐Díaz, Mauro Gacci, Andrea Salonia, Vincenzo Ficarra, Joaquı́n Carballido, A. Rodrı́guez-Antolı́n, José Medina‐Polo, J.M. Fernández Gómez, J.M. Cózar-Olmo, Santiago Búcar-Terrades, Noemí Pérez-León, Francisco Brenes-Bermúdez, José Molero, Antonio Fernández-Pro-Ledesma, Michael Herdman, J.C. Angulo, J. Dalmau, on behalf of the QUALIPROST Study Group

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review

34 citations , December 2021 in “Journal of Clinical Medicine”

Men with BPH should discuss potential sexual side effects with doctors before treatment, as some treatments can affect ejaculation.

research The Risk of Venous Thromboembolism in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors

6 citations , August 2021 in “Clinical Epidemiology”

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

research Association Between 5-Alpha Reductase Inhibitor Use and the Risk of Depression: A Meta-Analysis

3 citations , August 2020 in “Urology Journal”

Using 5-alpha reductase inhibitors may increase the risk of mild depression.

research Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm

17 citations , January 2020 in “The World Journal of Men's Health”

Long-term use of finasteride and dutasteride can cause serious health issues like diabetes and liver problems.

Sexual Dysfunction in Subjects Treated with Inhibitors of 5α-Reductase for Benign Prostatic Hyperplasia: A Comprehensive Review and Meta-Analysis

research Sexual Dysfunction in Subjects Treated with Inhibitors of 5α-Reductase for Benign Prostatic Hyperplasia: A Comprehensive Review and Meta-Analysis

66 citations , April 2017 in “International Journal of Andrology”

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

research Association of Suicidality and Depression With 5α-Reductase Inhibitors

90 citations , March 2017 in “JAMA Internal Medicine”

Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.

research 5α-Reductase Inhibitors Increase Acute Coronary Syndrome Risk in Patients with Benign Prostate Hyperplasia

6 citations , March 2015 in “Journal of Endocrinological Investigation”

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients with Benign Prostate Hyperplasia

research A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients with Benign Prostate Hyperplasia

22 citations , August 2014 in “Clinical endocrinology”

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

1707 citations , December 2003 in “The New England Journal of Medicine”

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.